Chiquita Brooks-LaSure testifies earlier than the Senate Finance Committee throughout her nomination listening to to be administrator of the Facilities for Medicare & Medicaid Companies in Washington on Thursday, April 15, 2021.
Caroline Brehman | CQ-Roll Name, Inc. | Getty Photos
In her first yr as administrator of the Facilities for Medicare and Medicaid Companies, Chiquita Brooks-Lasure has overseen the enlargement of presidency well being protection to a file variety of Individuals below Medicare, Medicaid and personal Reasonably priced Care Act trade plans.
Now, she desires to keep them insured, and increase entry to companies for ladies.
“We cowl over 150 million individuals on account of the entire onerous work of the company actually enrolling individuals in protection. So, we’re an enormous payer, and we assist dictate protection on this nation … and have a robust alternative to advance well being fairness,” Brooks-Lasure mentioned.
Within the yr forward, one of many company’s greatest challenges will probably be to create a clean transition for tens of millions of Medicaid members who may lose protection when the Covid public well being emergency ends. Beneath the federal well being emergency, states have put eligibility redeterminations on maintain for the final two years.
Whereas the administration is predicted to resume the present emergency designation subsequent month, a Kaiser Household Basis examine estimated that between 5 million and 14 million individuals could possibly be disenrolled when redeterminations resume.
Brooks-Lasure says well being insurers that administer state Medicaid packages will play an vital position to assist those that lose eligibility to transition to personal trade well being plans, or Medicare in the event that they’ve turned 65.
“We now have extra plan participation, significantly in Medicaid protection, than we did, say, 10 years in the past. So they’re a key part to serving to be sure that we — and by we, I additionally imply the states — transfer individuals to no matter kind of protection they’re eligible for,” she mentioned.
Even past the general public well being emergency, she desires well being protection to be extra constant throughout private and non-private packages.
“As a result of whether or not it is speaking about maternal well being otherwise you’re in the course of most cancers therapy … you need to keep targeted on the situation itself somewhat than having to fret about what modified in your protection,” she mentioned.
In a brand new report outlining priorities for the company, Brooks-Lasure says addressing well being disparities is a central pillar of the company’s mission. It has been particularly targeted on enhancing maternal well being protection; Medicaid packages now cowl 40% of births within the U.S. With funding from the American Rescue Plan Act, handed in 2021, the company is working with states to increase Medicaid protection for brand spanking new moms who’re uninsured from 60 days to 12 months.
Relating to reproductive care, Brooks-Lasure mentioned CMS may even prioritize enhancing entry to contraception in Medicaid and ACA well being plans within the yr forward. If the Supreme Courtroom overturns Roe v. Wade, as anticipated this month, the company will probably be restricted in its capability to supply entry to abortion for ladies on Medicaid below federal funding guidelines.
Brooks-Lasure mentioned the company was targeted on areas it has authority over, equivalent to preventative care and contraception. She mentioned CMS is encouraging states to make use of Medicaid to make sure women and men have entry to contraception, “in mild of regardless of the Supreme Courtroom determination is concerning broader companies.”
One of many greatest selections CMS issued this yr was to restrict Medicare protection for the Alzheimer’s therapy Aduhelm, after combined information on the drug’s efficacy. Nevertheless, the transfer got here after actuaries had factored within the anticipated excessive value of the drug into 2022 Medicare premiums. Medicare recipients can count on a rollback in 2023.
“As a result of protection is decrease, we’re going to incorporate that within the premium for subsequent yr,” Brooks-Lasure mentioned.
Medicare recipients may additionally get a break on drug plan premiums with the introduction of a number of biosimilar variations of AbbVie’s high-priced arthritis therapy Humira over the following yr. Humira gross sales topped $20 billion in 2021. Amgen’s biosimilar model would be the first to go on sale within the U.S., in January.
Brooks-Lasure mentioned CMS actuaries are calculating the potential affect of the transition to Humira biosimilars and are anticipated to launch their evaluation in early September, in time for setting 2023 premiums.